The Korea Times close
National
  • Politics
  • Foreign Affairs
  • Multicultural Community
  • Defense
  • Environment & Animals
  • Law & Crime
  • Society
  • Health & Science
Business
  • Tech
  • Bio
  • Companies
Finance
  • Companies
  • Economy
  • Markets
Opinion
  • Editorial
  • Columns
  • Thoughts of the Times
  • Cartoon
  • Today in History
  • Blogs
  • Tribune Service
  • Blondie & Garfield
  • Letter to President
  • Letter to the Editor
Lifestyle
  • Travel & Food
  • Trends
  • People & Events
  • Books
  • Around Town
  • Fortune Telling
Entertainment
& Arts
  • K-pop
  • Films
  • Shows & Dramas
  • Music
  • Theater & Others
Sports
World
  • SCMP
  • Asia
Video
  • Culture
  • People
  • News
Photos
  • Photo News
  • Darkroom
  • The Korea Times
  • search
  • Site Map
  • E-paper
  • Subscribe
  • Register
  • LogIn
search close
  • The Korea Times
  • search
  • Site Map
  • E-paper
  • Subscribe
  • Register
  • LogIn
search close
Business
  • Tech
  • Bio
  • Companies
Wed, May 25, 2022 | 07:40
Manufacturing
Samsung set to sign vaccine deal with Moderna
Posted : 2021-05-21 16:56
Updated : 2021-05-22 07:45
Print Preview
Font Size Up
Font Size Down
Vials with Pfizer-BioNTech and Moderna coronavirus disease (COVID-19) vaccine labels are seen in this illustration picture taken March 19. Reuters-Yonhap
Vials with Pfizer-BioNTech and Moderna coronavirus disease (COVID-19) vaccine labels are seen in this illustration picture taken March 19. Reuters-Yonhap

By Kim Yoo-chul

Samsung Biologics is set to sign an agreement with Moderna under which the Samsung Group's biotechnology affiliate will manufacture the U.S. pharmacology firm's messenger RNA (mRNA)-based COVID vaccine at its plant in South Korea, according to a high-ranking government official, Friday.

The official, with knowledge of the matter, said a government delegation is set to meet with officials of Moderna and Novavax in Washington D.C on the sidelines of the summit between President Moon Jae-in with U.S. President Joe Biden,.

"Samsung Biologics is planned to sign an MOU with Moderna, while SK Biosicence is looking to reach an agreement with Novavax. Under the agreements, the two South Korean companies will be allowed to manufacture their partner's COVID-19 vaccines. President Moon is planning to attend a signing ceremony for the deals," he said.

Moderna COVID-19 vaccine gets final nod in Korea
Moderna COVID-19 vaccine gets final nod in Korea
2021-05-21 14:46  |  Health & Science

Details regarding the amount of vaccine Samsung Biologics could produce as well as the timing of production and possibility of technology transfers remain to be discussed in person-to-person meetings, the official added. The Korean firm is still weak in terms of having core patents for the in-house development of mRNA vaccines.

The potential Samsung-Moderna partnership comes after Seoul approved the use of the latter's COVID vaccine to speed up its vaccination program. Moderna has already signed a deal to supply up to 40 million doses of its vaccines, although delivery dates have yet to be fixed.

In addition, the official said there was little possibility of the delegation discussing getting additional Moderna vaccine. The company plans to manufacture 700 million doses this year.

"It's unlikely that the delegation can reach a vaccine deal with Pfizer, as the top issue on President Moon's visit to Washington is how to explore making South Korea Asia's vaccine hub," another government official said.

Regarding the SK Bioscience-Novavax partnership, the officials said the parties were set to finalize the details on how to jointly develop projects regarding research into COVID vaccines with the two sharing technology.

The government's vaccination campaign has been hampered by a global shortage and shipment delays. It has provided doses to just over 7 percent of its 52 million residents so far, as it aims to inoculate at least 13 million by June and reach herd immunity by November.

Moon said previously that he will discuss vaccine and North Korea issues at his summit with Biden.



Emailyckim@koreatimes.co.kr Article ListMore articles by this reporter
 
  • 75th Cannes Film Festival
  • Attention needed to end modern-day slavery
  • [INTERVIEW] How brewery waste turned into pizza dough, energy bars at RE:harvest
  • Ex-Gyeryong mayor found dead after losing nomination in local elections
  • Labor union opposes resumption of late-night subway operations
  • Samsung to invest 450 trillion won to cement lead in chip, bio sectors
  • Gov't to ease tax burden that increased during previous administration
  • Mother charged with killing disabled daughter
  • Japan hosts Quad summit seeking unity on countering China
  • Premier League Golden Boot winner Son Heung-min receives hero's welcome home
  • 'GOT7 has not disbanded' 'GOT7 has not disbanded'
  • Hollywood blockbuster sequels poised to hit theaters, streaming platforms Hollywood blockbuster sequels poised to hit theaters, streaming platforms
  • Girl group NiziU to begin 1st Japanese tour Girl group NiziU to begin 1st Japanese tour
  • Actor's short film 'Dark Yellow' nominated for Asia competition at Japan's film festival Actor's short film 'Dark Yellow' nominated for Asia competition at Japan's film festival
  • 'The Roundup' lures 2.5 million moviegoers over weekend 'The Roundup' lures 2.5 million moviegoers over weekend
DARKROOM
  • 75th Cannes Film Festival

    75th Cannes Film Festival

  • People in North Korea trapped in famine and pandemic

    People in North Korea trapped in famine and pandemic

  • 2022 Pulitzer Prize: Bearing witness to history

    2022 Pulitzer Prize: Bearing witness to history

  • Worsening drought puts millions at risk

    Worsening drought puts millions at risk

  • Our children deserve the best

    Our children deserve the best

The Korea Times
CEO & Publisher : Oh Young-jin
Digital News Email : webmaster@koreatimes.co.kr
Tel : 02-724-2114
Online newspaper registration No : 서울,아52844
Date of registration : 2020.02.05
Masthead : The Korea Times
Copyright © koreatimes.co.kr. All rights reserved.
  • About Us
  • Introduction
  • History
  • Location
  • Media Kit
  • Contact Us
  • Products & Service
  • Subscribe
  • E-paper
  • Mobile Service
  • RSS Service
  • Content Sales
  • Policy
  • Privacy Statement
  • Terms of Service
  • 고충처리인
  • Youth Protection Policy
  • Code of Ethics
  • Copyright Policy
  • Family Site
  • Hankook Ilbo
  • Dongwha Group